Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: Preliminary results of an ongoing prospectively randomized multicentre study

Transplant International

Volumn 18, Issue 6, 2005, Pages 703-708

  Reinhard, Thomas ^a,e   Mayweg, Susanne ^b   Sokolovska, Yewgenia ^b   Seitz, Berthold ^c   Mittelviefhaus, Hans ^a   Engelmann, Katrin ^d   Voiculescu, Adina ^b   Godehardt, Erhard ^b   Sundmacher, Rainer ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e NONE   (Germany)

Author keywords

Graft survival; Keratoplasty; Mofetil; Mycophenolate; Rejection

Indexed keywords

FLUOCORTOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE ACETATE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; AGED; ARTHRALGIA; ASTHMA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; FOLLOW UP; GRAFT SURVIVAL; HUMAN; IMMUNITY; INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OUTCOMES RESEARCH; PENETRATING KERATOPLASTY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; ARTICLE; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES;

EID: 23244452959     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00126.x     Document Type: Conference Paper

References (28)

1. Morris R, Hoyt E, Murphy P. Mycophenolic acid (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22: 1659.
2. European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin A and corticosteroids for the prevention of acute rejection. Lancet 1995; 345: 1321.
3. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3 years results from the placebo-controlled trial. Transplantation 1999; 68: 391.
4. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
5. Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002; 21: 282.
6. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442.
7. Hill JC. The use of cyclosporine in high risk keratoplasty. Am J Ophthalmol 1989; 107: 506.
8. Hill JC. Systemic cyclosporine in high risk keratoplasty. Short-versus long-term therapy. Ophthalmology 1994; 101: 128.
9. Reinhard T, Sundmacher R. Systemische Cyclosporin-A Prophylaxe nach Keratoplastiken mit erhöhtem Risiko für Immunreaktionen als einzigem erhöhten Risikofaktor. Ophthalmologe 1997; 94: 496.
10. Reis A, Reinhard T, Voiculescu A, et al. Mycophenolate mofetil versus cyclosporin A in high-risk keratoplasty patients: a prospective, randomised clinical trial. Br J Ophthalmol 1999; 83: 1268.
11. Reinhard T, Reis A, Böhringer D, et al. Systemic nycophenolate mofetil (MMF) in comparison to systemic cyclosporin A (CsA) in high risk keratoplasty patients. Three years' results of a randomised prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 2001; 239: 367.]
12. Reis A, Reinhard T, Godehardt E, Braunstein S, Sundmacher R. Effect of mycophenolate mofetil, cyclosporin A, and both in a murine corneal graft rejection model. Br J Ophthalmol 1998; 82: 700.
13. Reis A, Megahed H, Reinhard T, et al. Coadministration of the new macrolide RAD and mycophenolate mofetil in experimental corneal transplantation. Transplantation 2000; 70: 1397.
14. Sundmacher R. Immunreaktionen nach Keratoplastik. Klin Monatsbl Augenheilkd 1977; 171: 705.
15. Sundmacher R, Steffanson A, Mackensen G. Verlaufsbeobachtungen nach Keratoplastik. Klin Monatsbl Augenheilkd 1983; 80: 224.
16. Alldredge OC, Krachmer JH. Clinical types of corneal transplant reaction. Arch Ophthalmol 1981; 99: 599.
17. Reinhard T, Hutmacher M, Sundmacher R, Godehardt E. Akute und chronische Immunreaktionen nach perforierender Keratoplastik mit normalem Immunrisiko. Klin Monatsbl Augenheilkd 1997; 210: 139.
18. Böhringer D, Reinhard T, Godehardt E, Sundmacher R. Regressionsanalyse des idiopathischen Endothelzellverlustes nach perforierender Keratoplastik. Klin Monatsbl Augenheilkd 2001; 218: 412.
19. Langenbucher A, Nguyen NX, Kus MM, Blüthner K, Küchle M, Seitz B. Regressionsverhalten des Hornhautendothels nach nichtmechanischer perforierender Keratoplastik. Klin Monatsbl Augenheilkd 2000; 216: 393.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
21. Streilein JW, Yamada J, Dana MR, Ksander BR. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant Proc 1999; 31: 1472.
22. Girard LJ, Esnaolo N, Rao R. Allograft rejection after penetrating keratoplasty for keratoconus. Ophthalmic Surg 1993; 24: 40.
23. Sharif KW, Casey TA. Penetrating keratoplasty for keratoconus: complications and long-term success. Br J Ophthalmol 1991; 75: 142.
24. Troutman RC, Lawless MA. Penetrating keratoplasty for keratoconus. Cornea 1987; 6: 298.
25. Kamp MT, Fink NE, Enger C, Maguire MG, Stark WJ, Stulting RD. Patient-reported symptoms associated with graft reactions in high-risk patients in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Cornea 1995; 14: 43.
26. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999; 106: 370.
27. Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003; 110: 1061.
28. 2) in the aqueous tumor of patients with endothelial immune reactions after penetrating keratoplasty (KP). Arch Ophthalmol 2002; 120: 1630.